1887

Abstract

Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4 memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host, but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.049296-0
2013-05-01
2021-03-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/5/917.html?itemId=/content/journal/jgv/10.1099/vir.0.049296-0&mimeType=html&fmt=ahah

References

  1. Ackley C. D., Yamamoto J. K., Levy N., Pedersen N. C., Cooper M. D. 1990; Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 64:5652–5655[PubMed]
    [Google Scholar]
  2. Alexaki A., Wigdahl B. 2008; HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog 4:e1000215 [CrossRef][PubMed]
    [Google Scholar]
  3. Allers K., Hütter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., Schneider T. 2011; Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117:2791–2799 [CrossRef][PubMed]
    [Google Scholar]
  4. Anderson J., Li M.-J., Palmer B., Remling L., Li S., Yam P., Yee J.-K., Rossi J., Zaia J., Akkina R. 2007; Safety and efficacy of a lentiviral vector containing three anti-HIV genes–CCR5 ribozyme, tat-rev siRNA, and TAR decoy–in SCID-hu mouse-derived T cells. Mol Ther 15:1182–1188[PubMed] [CrossRef]
    [Google Scholar]
  5. Archin N. M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D. M. 2009; Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25:207–212 [CrossRef][PubMed]
    [Google Scholar]
  6. Archin N. M., Liberty A. L., Kashuba A. D., Choudhary S. K., Kuruc J. D., Crooks A. M., Parker D. C., Anderson E. M., Kearney M. F. other authors 2012; Administration of Vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482–485 [CrossRef][PubMed]
    [Google Scholar]
  7. Assogba B. D., Leavell S., Porter K., Burkhard M. J. 2007; Mucosal administration of low-dose cell-associated feline immunodeficiency virus promotes viral latency. J Infect Dis 195:1184–1188 [CrossRef][PubMed]
    [Google Scholar]
  8. Bai J., Gorantla S., Banda N., Cagnon L., Rossi J., Akkina R. 2000; Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo . Mol Ther 1:244–254 [CrossRef][PubMed]
    [Google Scholar]
  9. Bailey J. R., Sedaghat A. R., Kieffer T., Brennan T., Lee P. K., Wind-Rotolo M., Haggerty C. M., Kamireddi A. R., Liu Y. other authors 2006; Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80:6441–6457 [CrossRef][PubMed]
    [Google Scholar]
  10. Baldauf H. M., Pan X., Erikson E., Schmidt S., Daddacha W., Burggraf M., Schenkova K., Ambiel I., Wabnitz G. other authors 2012; SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat Med 18:1682–1689 [CrossRef][PubMed]
    [Google Scholar]
  11. Banerjee C., Archin N., Michaels D., Belkina A. C., Denis G. V., Bradner J., Sebastiani P., Margolis D. M., Montano M. 2012; BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92:1147–1154 [CrossRef][PubMed]
    [Google Scholar]
  12. Barlough J. E., Ackley C. D., George J. W., Levy N., Acevedo R., Moore P. F., Rideout B. A., Cooper M. D., Pedersen N. C. 1991; Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr 4:219–227[PubMed]
    [Google Scholar]
  13. Beatty J. A., Willett B. J., Gault E. A., Jarrett O. 1996; A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J Virol 70:6199–6206[PubMed]
    [Google Scholar]
  14. Bebenek K., Abbotts J., Wilson S. H., Kunkel T. A. 1993; Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem 268:10324–10334[PubMed]
    [Google Scholar]
  15. Benkirane M., Chun R. F., Xiao H., Ogryzko V. V., Howard B. H., Nakatani Y., Jeang K. T. 1998; Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 273:24898–24905 [CrossRef][PubMed]
    [Google Scholar]
  16. Berard M., Tough D. F. 2002; Qualitative differences between naïve and memory T cells. Immunology 106:127–138 [CrossRef][PubMed]
    [Google Scholar]
  17. Best B. M., Letendre S. L., Koopmans P., Rossi S. S., Clifford D. B., Collier A. C., Gelman B. B., Marra C. M., McArthur J. C. other authors 2012; Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 59:376–381 [CrossRef][PubMed]
    [Google Scholar]
  18. Biancotto A., Grivel J.-C., Gondois-Rey F., Bettendroffer L., Vigne R., Brown S., Margolis L. B., Hirsch I. 2004; Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78:10507–10515 [CrossRef][PubMed]
    [Google Scholar]
  19. Blazkova J., Trejbalova K., Gondois-Rey F., Halfon P., Philibert P., Guiguen A., Verdin E., Olive D., Van Lint C. other authors 2009; CpG methylation controls reactivation of HIV from latency. PLoS Pathog 5:e1000554 [CrossRef][PubMed]
    [Google Scholar]
  20. Bleul C. C., Wu L. J., Hoxie J. A., Springer T. A., Mackay C. R. 1997; The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 94:1925–1930 [CrossRef][PubMed]
    [Google Scholar]
  21. Boberg A., Bråve A., Johansson S., Wahren B., Hinkula J., Rollman E. 2008; Murine models for HIV vaccination and challenge. Expert Rev Vaccines 7:117–130 [CrossRef][PubMed]
    [Google Scholar]
  22. Bosque A., Planelles V. 2009; Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58–65 [CrossRef][PubMed]
    [Google Scholar]
  23. Bosque A., Famiglietti M., Weyrich A. S., Goulston C., Planelles V. 2011; Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 7:e1002288 [CrossRef][PubMed]
    [Google Scholar]
  24. Brenchley J. M., Paiardini M. 2011; Immunodeficiency lentiviral infections in natural and non-natural hosts. Blood 118:847–854 [CrossRef][PubMed]
    [Google Scholar]
  25. Brenchley J. M., Schacker T. W., Ruff L. E., Price D. A., Taylor J. H., Beilman G. J., Nguyen P. L., Khoruts A., Larson M. other authors 2004a; CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749–759 [CrossRef][PubMed]
    [Google Scholar]
  26. Brenchley J. M., Hill B. J., Ambrozak D. R., Price D. A., Guenaga F. J., Casazza J. P., Kuruppu J., Yazdani J., Migueles S. A. other authors 2004b; T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78:1160–1168 [CrossRef][PubMed]
    [Google Scholar]
  27. Brennan T. P., Woods J. O., Sedaghat A. R., Siliciano J. D., Siliciano R. F., Wilke C. O. 2009; Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 83:8470–8481 [CrossRef][PubMed]
    [Google Scholar]
  28. Brooks D. G., Kitchen S. G., Kitchen C. M. R., Scripture-Adams D. D., Zack J. A. 2001; Generation of HIV latency during thymopoiesis. Nat Med 7:459–464 [CrossRef][PubMed]
    [Google Scholar]
  29. Bukrinsky M. I., Stanwick T. L., Dempsey M. P., Stevenson M. 1991; Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423–427 [CrossRef][PubMed]
    [Google Scholar]
  30. Burke B., Brown H. J., Marsden M. D., Bristol G., Vatakis D. N., Zack J. A. 2007; Primary cell model for activation-inducible human immunodeficiency virus. J Virol 81:7424–7434 [CrossRef][PubMed]
    [Google Scholar]
  31. Burnett J. C., Rossi J. J. 2012; RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60–71 [CrossRef][PubMed]
    [Google Scholar]
  32. Burnett J. C., Lim K. I., Calafi A., Rossi J. J., Schaffer D. V., Arkin A. P. 2010; Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 84:5958–5974 [CrossRef][PubMed]
    [Google Scholar]
  33. Buzón M. J., Massanella M., Llibre J. M., Esteve A., Dahl V., Puertas M. C., Gatell J. M., Domingo P., Paredes R. other authors 2010; HIV-1 replication and immune dynamics are affected by Raltegravir intensification of HAART-suppressed subjects. Nat Med 16:460–465 [CrossRef][PubMed]
    [Google Scholar]
  34. Cabrita G. J. M., Ferreira B. S., da Silva C. L., Gonçalves R., Almeida-Porada G., Cabral J. M. S. 2003; Hematopoietic stem cells: from the bone to the bioreactor. Trends Biotechnol 21:233–240 [CrossRef][PubMed]
    [Google Scholar]
  35. Canestri A., Lescure F.-X., Jaureguiberry S., Moulignier A., Amiel C., Marcelin A. G., Peytavin G., Tubiana R., Pialoux G., Katlama C. 2010; Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773–778 [CrossRef][PubMed]
    [Google Scholar]
  36. Carter C. C., Onafuwa-Nuga A., McNamara L. A., Riddell J. IV, Bixby D., Savona M. R., Collins K. L. 2010; HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16:446–451 [CrossRef][PubMed]
    [Google Scholar]
  37. Carter C. C., McNamara L. A., Onafuwa-Nuga A., Shackleton M., Riddell J. IV, Bixby D., Savona M. R., Morrison S. J., Collins K. L. 2011; HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9:223–234 [CrossRef][PubMed]
    [Google Scholar]
  38. Chahroudi A., Bosinger S. E., Vanderford T. H., Paiardini M., Silvestri G. 2012; Natural SIV hosts: showing AIDS the door. Science 335:1188–1193 [CrossRef][PubMed]
    [Google Scholar]
  39. Chan C. N., McMonagle E. L., Hosie M. J., Willett B. J. 2013; Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4+ T-cells. Virus Res 171:121–128 [CrossRef][PubMed]
    [Google Scholar]
  40. Chen L. F., Mu Y., Greene W. C. 2002; Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 21:6539–6548 [CrossRef][PubMed]
    [Google Scholar]
  41. Chiang K., Rice A. P. 2012; MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses 4:1390–1409 [CrossRef][PubMed]
    [Google Scholar]
  42. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G. other authors 1996; The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135–1148 [CrossRef][PubMed]
    [Google Scholar]
  43. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F. A., Yassine-Diab B., Boucher G., Boulassel M.-R., Ghattas G. other authors 2009; HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893–900 [CrossRef][PubMed]
    [Google Scholar]
  44. Choudhary S. K., Rezk N. L., Ince W. L., Cheema M., Zhang L., Su L., Swanstrom R., Kashuba A. D., Margolis D. M. 2009; Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2–/–γc–/– mouse. J Virol 83:8254–8258 [CrossRef][PubMed]
    [Google Scholar]
  45. Choudhary S. K., Archin N. M., Cheema M., Dahl N. P., Garcia J. V., Margolis D. M. 2012; Latent HIV-1 infection of resting CD4+ T cells in the humanized Rag2−/− γc−/− mouse. J Virol 86:114–120 [CrossRef][PubMed]
    [Google Scholar]
  46. Chun T. W., Finzi D., Margolick J., Chadwick K., Schwartz D., Siliciano R. F. 1995; In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1:1284–1290 [CrossRef][PubMed]
    [Google Scholar]
  47. Chun T. W., Carruth L., Finzi D., Shen X., DiGiuseppe J. A., Taylor H., Hermankova M., Chadwick K., Margolick J. other authors 1997; Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183–188 [CrossRef][PubMed]
    [Google Scholar]
  48. Chun T. W., Engel D., Mizell S. B., Ehler L. A., Fauci A. S. 1998; Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188:83–91 [CrossRef][PubMed]
    [Google Scholar]
  49. Chun T. W., Davey R. T. Jr, Engel D., Lane H. C., Fauci A. S. 1999; Re-emergence of HIV after stopping therapy. Nature 401:874–875 [CrossRef][PubMed]
    [Google Scholar]
  50. Chun T. W., Nickle D. C., Justement J. S., Large D., Semerjian A., Curlin M. E., O’Shea M. A., Hallahan C. W., Daucher M. other authors 2005; HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115:3250–3255 [CrossRef][PubMed]
    [Google Scholar]
  51. Chun T.-W., Nickle D. C., Justement J. S., Meyers J. H., Roby G., Hallahan C. W., Kottilil S., Moir S., Mican J. M. other authors 2008; Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197:714–720 [CrossRef][PubMed]
    [Google Scholar]
  52. Churchill M. J., Gorry P. R., Cowley D., Lal L., Sonza S., Purcell D. F. J., Thompson K. A., Gabuzda D., McArthur J. C. other authors 2006; Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 12:146–152 [CrossRef][PubMed]
    [Google Scholar]
  53. Cicala C., Arthos J., Censoplano N., Cruz C., Chung E., Martinelli E., Lempicki R. A., Natarajan V., VanRyk D. other authors 2006; HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology 345:105–114 [CrossRef][PubMed]
    [Google Scholar]
  54. Cillo A., Krishnan A., Mitsuyasu R., McMahon D., Li S., Rossi J., Zaia J., Mellors J. W. 2012; Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for AIDS-related lymphoma. In CROI Seattle, USA:
    [Google Scholar]
  55. Coffer P. J., Burgering B. M. 2004; Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4:889–899 [CrossRef][PubMed]
    [Google Scholar]
  56. Coiras M., López-Huertas M. R., Pérez-Olmeda M., Alcamí J. 2009; Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7:798–812 [CrossRef][PubMed]
    [Google Scholar]
  57. Coleman C. M., Wu L. 2009; HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6:51 [CrossRef][PubMed]
    [Google Scholar]
  58. Colin L., Van Lint C. 2009; Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111 [CrossRef][PubMed]
    [Google Scholar]
  59. Connor R. I., Sheridan K. E., Ceradini D., Choe S., Landau N. R. 1997; Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med 185:621–628 [CrossRef][PubMed]
    [Google Scholar]
  60. Contreras X., Schweneker M., Chen C.-S., McCune J. M., Deeks S. G., Martin J., Peterlin B. M. 2009; Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284:6782–6789 [CrossRef][PubMed]
    [Google Scholar]
  61. Coull J. J., Romerio F., Sun J. M., Volker J. L., Galvin K. M., Davie J. R., Shi Y., Hansen U., Margolis D. M. 2000; The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74:6790–6799 [CrossRef][PubMed]
    [Google Scholar]
  62. d’Arminio A., Sabin C. A., Phillips A. N., Reiss P., Weber R., Kirk O., El-Sadr W., De Wit S., Mateu S. other authors 2004; Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18:1811–1817 [CrossRef][PubMed]
    [Google Scholar]
  63. Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss R. A. 1984; The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763–767 [CrossRef][PubMed]
    [Google Scholar]
  64. Davey R. T. Jr, Bhat N., Yoder C., Chun T. W., Metcalf J. A., Dewar R., Natarajan V., Lempicki R. A., Adelsberger J. W. other authors 1999; HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96:15109–15114 [CrossRef][PubMed]
    [Google Scholar]
  65. Davis B. R., Schwartz D. H., Marx J. C., Johnson C. E., Berry J. M., Lyding J., Merigan T. C., Zander A. 1991; Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 65:1985–1990[PubMed]
    [Google Scholar]
  66. Dean M., Carrington M., Winkler C., Huttley G. A., Smith M. W., Allikmets R., Goedert J. J., Buchbinder S. P., Vittinghoff E. other authors 1996; Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856–1862 [CrossRef][PubMed]
    [Google Scholar]
  67. Deeks S. G. 2011; HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155 [CrossRef][PubMed]
    [Google Scholar]
  68. Deeks S. G., Autran B., Berkhout B., Benkirane M., Cairns S., Chomont N., Chun T. W., Churchill M., Di Mascio M. other authors 2012; Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12:607–614 [CrossRef][PubMed]
    [Google Scholar]
  69. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E. other authors 1996; Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666 [CrossRef][PubMed]
    [Google Scholar]
  70. Descours B., Cribier A., Chable-Bessia C., Ayinde D., Rice G., Crow Y., Yatim A., Schwartz O., Laguette N., Benkirane M. 2012; SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells. Retrovirology 9:87 [CrossRef][PubMed]
    [Google Scholar]
  71. Di Mascio M., Srinivasula S., Bhattacharjee A., Cheng L., Martiniova L., Herscovitch P., Lertora J., Kiesewetter D. 2009; Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother 53:4086–4095 [CrossRef][PubMed]
    [Google Scholar]
  72. Dinoso J. B., Rabi S. A., Blankson J. N., Gama L., Mankowski J. L., Siliciano R. F., Zink M. C., Clements J. E. 2009a; A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 83:9247–9257 [CrossRef][PubMed]
    [Google Scholar]
  73. Dinoso J. B., Kim S. Y., Wiegand A. M., Palmer S. E., Gange S. J., Cranmer L., O’Shea A., Callender M., Spivak A. other authors 2009b; Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106:9403–9408 [CrossRef][PubMed]
    [Google Scholar]
  74. Douek D. C., Roederer M., Koup R. A. 2009; Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60:471–484 [CrossRef][PubMed]
    [Google Scholar]
  75. Durand C. M., Ghiaur G., Siliciano J. D., Rabi S. A., Eisele E. E., Salgado M., Shan L., Lai J. F., Zhang H. other authors 2012; HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 205:1014–1018 [CrossRef][PubMed]
    [Google Scholar]
  76. Egberink H. F., Keldermans C. E., Koolen M. J., Horzinek M. C. 1992; Humoral immune response to feline immunodeficiency virus in cats with experimentally induced and naturally acquired infections. Am J Vet Res 53:1133–1138[PubMed]
    [Google Scholar]
  77. Eichbaum Q. 2011; PD-1 signaling in HIV and chronic viral infection–potential for therapeutic intervention?. Curr Med Chem 18:3971–3980 [CrossRef][PubMed]
    [Google Scholar]
  78. Eisele E., Siliciano R. F. 2012; Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377–388 [CrossRef][PubMed]
    [Google Scholar]
  79. Else L. J., Taylor S., Back D. J., Khoo S. H. 2011; Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 16:1149–1167 [CrossRef][PubMed]
    [Google Scholar]
  80. Feng Y., Broder C. C., Kennedy P. E., Berger E. A. 1996; HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872–877 [CrossRef][PubMed]
    [Google Scholar]
  81. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W. B., Fedorov O., Morse E. M., Keates T., Hickman T. T. other authors 2010; Selective inhibition of BET bromodomains. Nature 468:1067–1073 [CrossRef][PubMed]
    [Google Scholar]
  82. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J. other authors 1997; Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300 [CrossRef][PubMed]
    [Google Scholar]
  83. Flynn J. N., Dunham S., Mueller A., Cannon C., Jarrett O. 2002; Involvement of cytolytic and non-cytolytic T cells in the control of feline immunodeficiency virus infection. Vet Immunol Immunopathol 85:159–170 [CrossRef][PubMed]
    [Google Scholar]
  84. Folks T. M., Justement J., Kinter A., Dinarello C. A., Fauci A. S. 1987; Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800–802 [CrossRef][PubMed]
    [Google Scholar]
  85. Folks T. M., Kessler S. W., Orenstein J. M., Justement J. S., Jaffe E. S., Fauci A. S. 1988; Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 242:919–922 [CrossRef][PubMed]
    [Google Scholar]
  86. Folks T. M., Clouse K. A., Justement J., Rabson A., Duh E., Kehrl J. H., Fauci A. S. 1989; Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365–2368 [CrossRef][PubMed]
    [Google Scholar]
  87. Gabriel R., Lombardo A., Arens A., Miller J. C., Genovese P., Kaeppel C., Nowrouzi A., Bartholomae C. C., Wang J. other authors 2011; An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29:816–823 [CrossRef][PubMed]
    [Google Scholar]
  88. Gandhi R. T., Zheng L., Bosch R. J., Chan E. S., Margolis D. M., Read S., Kallungal B., Palmer S., Medvik K. other authors 2010; The effect of Raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7:e1000321 [CrossRef][PubMed]
    [Google Scholar]
  89. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. 1986; The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215–219 [CrossRef][PubMed]
    [Google Scholar]
  90. Ghose R., Liou L. Y., Herrmann C. H., Rice A. P. 2001; Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4+ T lymphocytes by combination of cytokines. J Virol 75:11336–11343 [CrossRef][PubMed]
    [Google Scholar]
  91. Goldman J. P., Blundell M. P., Lopes L., Kinnon C., Di Santo J. P., Thrasher A. J. 1998; Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 103:335–342 [CrossRef][PubMed]
    [Google Scholar]
  92. González-Scarano F., Martín-García J. 2005; The neuropathogenesis of AIDS. Nat Rev Immunol 5:69–81 [CrossRef][PubMed]
    [Google Scholar]
  93. Greger I. H., Demarchi F., Giacca M., Proudfoot N. J. 1998; Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. Nucleic Acids Res 26:1294–1301 [CrossRef][PubMed]
    [Google Scholar]
  94. Gutiérrez C., Díaz L., Vallejo A., Hernández-Novoa B., Abad M., Madrid N., Dahl V., Rubio R., Moreno A. M. other authors 2011; Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE 6:e27864 [CrossRef][PubMed]
    [Google Scholar]
  95. Haaland R. E., Yu W., Rice A. P. 2005; Identification of LKLF-regulated genes in quiescent CD4+ T lymphocytes. Mol Immunol 42:627–641 [CrossRef][PubMed]
    [Google Scholar]
  96. Halfon P., Giorgetti C., Khiri H., Pénaranda G., Terriou P., Porcu-Buisson G., Chabert-Orsini V. 2010; Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS ONE 5:e10569 [CrossRef][PubMed]
    [Google Scholar]
  97. Han Y., Lassen K., Monie D., Sedaghat A. R., Shimoji S., Liu X., Pierson T. C., Margolick J. B., Siliciano R. F., Siliciano J. D. 2004; Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 78:6122–6133 [CrossRef][PubMed]
    [Google Scholar]
  98. Han Y., Wind-Rotolo M., Yang H. C., Siliciano J. D., Siliciano R. F. 2007; Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 5:95–106 [CrossRef][PubMed]
    [Google Scholar]
  99. Han Y., Lin Y. B., An W., Xu J., Yang H. C., O’Connell K., Dordai D., Boeke J. D., Siliciano J. D., Siliciano R. F. 2008; Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4:134–146 [CrossRef][PubMed]
    [Google Scholar]
  100. Hatano H., Hayes T. L., Dahl V., Sinclair E., Lee T. H., Hoh R., Lampiris H., Hunt P. W., Palmer S. other authors 2011; A randomized, controlled trial of Raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 203:960–968 [CrossRef][PubMed]
    [Google Scholar]
  101. Hecht R., Stover J., Bollinger L., Muhib F., Case K., de Ferranti D. 2010; Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 376:1254–1260 [CrossRef][PubMed]
    [Google Scholar]
  102. Hermankova M., Siliciano J. D., Zhou Y., Monie D., Chadwick K., Margolick J. B., Quinn T. C., Siliciano R. F. 2003; Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 77:7383–7392 [CrossRef][PubMed]
    [Google Scholar]
  103. Hesselton R. M., Greiner D. L., Mordes J. P., Rajan T. V., Sullivan J. L., Shultz L. D. 1995; High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 172:974–982 [CrossRef][PubMed]
    [Google Scholar]
  104. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M. Jr, Elkins W. R., Alvord W. G. other authors 1996; Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741–3752[PubMed]
    [Google Scholar]
  105. Hirsch V. M., Lifson J. D., Kuah-Teh J. 2000; Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. In Advances in Pharmacology vol. 49 pp. 437–477 Academic Press; [CrossRef]
    [Google Scholar]
  106. Ho D. D., Rota T. R., Hirsch M. S. 1986; Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest 77:1712–1715 [CrossRef][PubMed]
    [Google Scholar]
  107. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. 1995; Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126 [CrossRef][PubMed]
    [Google Scholar]
  108. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G. M., Kohn D. B., Gregory P. D. other authors 2010; Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28:839–847 [CrossRef][PubMed]
    [Google Scholar]
  109. Hosie M. J., Pajek D., Samman A., Willett B. J. 2011; Feline immunodeficiency virus (FIV) neutralization: a review. Viruses 3:1870–1890 [CrossRef][PubMed]
    [Google Scholar]
  110. Howard K. E., Reckling S. K., Egan E. A., Dean G. A. 2010; Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats. Retrovirology 7:2 [CrossRef][PubMed]
    [Google Scholar]
  111. Hütter G., Nowak D., Mossner M., Ganepola S., Müssig A., Allers K., Schneider T., Hofmann J., Kücherer C. other authors 2009; Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360:692–698 [CrossRef][PubMed]
    [Google Scholar]
  112. Joos B., Fischer M., Kuster H., Pillai S. K., Wong J. K., Böni J., Hirschel B., Weber R., Trkola A., Günthard H. F. Swiss HIV Cohort Study 2008; HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 105:16725–16730 [CrossRef][PubMed]
    [Google Scholar]
  113. Jordan A., Bisgrove D., Verdin E. 2003; HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22:1868–1877 [CrossRef][PubMed]
    [Google Scholar]
  114. Josefsson L., Eriksson S., Sinclair E., Ho T., Killian M., Epling L., Shao W., Lewis B., Bacchetti P. other authors 2012; Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 206:28–34 [CrossRef][PubMed]
    [Google Scholar]
  115. Joshi A., Vahlenkamp T. W., Garg H., Tompkins W. A. F., Tompkins M. B. 2004; Preferential replication of FIV in activated CD4+CD25+T cells independent of cellular proliferation. Virology 321:307–322 [CrossRef][PubMed]
    [Google Scholar]
  116. Joshi A., Garg H., Tompkins M. B., Tompkins W. A. 2005; Different thresholds of T cell activation regulate FIV infection of CD4+CD25+ and CD4+CD25- cells. Virology 335:212–221 [CrossRef][PubMed]
    [Google Scholar]
  117. June C., Pablo T., Stein D., Mitsuyasu R., Lalezari J., Wang S., Lee G., Levine B., Tang W. other authors 2012; Induction of acquired CCR5 deficiency with zinc finger nuclease-modified autologous CD4 T cells (SB-728-T) correlates with increases in CD4 count and effects on viral load in HIV-infected subjects. In 19th Conference on Retroviruses and Opportunistic Infections (CROI)
  118. Kauder S. E., Bosque A., Lindqvist A., Planelles V., Verdin E. 2009; Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495 [CrossRef][PubMed]
    [Google Scholar]
  119. Kerr J. S., Galloway S., Lagrutta A., Armstrong M., Miller T., Richon V. M., Andrews P. A. 2010; Nonclinical safety assessment of the histone deacetylase inhibitor Vorinostat. Int J Toxicol 29:3–19 [CrossRef][PubMed]
    [Google Scholar]
  120. Kornfeld H., Cruikshank W. W., Pyle S. W., Berman J. S., Center D. M. 1988; Lymphocyte activation by HIV-1 envelope glycoprotein. Nature 335:445–448 [CrossRef][PubMed]
    [Google Scholar]
  121. Kraase M., Sloan R., Klein D., Logan N., McMonagle L., Biek R., Willett B. J., Hosie M. J. 2010; Feline immunodeficiency virus env gene evolution in experimentally infected cats. Vet Immunol Immunopathol 134:96–106 [CrossRef][PubMed]
    [Google Scholar]
  122. Kulkosky J., Culnan D. M., Roman J., Dornadula G., Schnell M., Boyd M. R., Pomerantz R. J. 2001; Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98:3006–3015 [CrossRef][PubMed]
    [Google Scholar]
  123. Kumar P., Ban H.-S., Kim S.-S., Wu H., Pearson T., Greiner D. L., Laouar A., Yao J., Haridas V. other authors 2008; T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134:577–586 [CrossRef][PubMed]
    [Google Scholar]
  124. Kwara A., Delong A., Rezk N., Hogan J., Burtwell H., Chapman S., Moreira C. C., Kurpewski J., Ingersoll J. other authors 2008; Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 46:719–725 [CrossRef][PubMed]
    [Google Scholar]
  125. Kwon H. S., Brent M. M., Getachew R., Jayakumar P., Chen L. F., Schnolzer M., McBurney M. W., Marmorstein R., Greene W. C., Ott M. 2008; Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3:158–167 [CrossRef][PubMed]
    [Google Scholar]
  126. Lassen K. G., Bailey J. R., Siliciano R. F. 2004; Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 78:9105–9114 [CrossRef][PubMed]
    [Google Scholar]
  127. Lassen K. G., Ramyar K. X., Bailey J. R., Zhou Y., Siliciano R. F. 2006; Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2:e68 [CrossRef][PubMed]
    [Google Scholar]
  128. Launay O., Tod M., Tschöpe I., Si-Mohamed A., Bélarbi L., Charpentier C., Goujard C., Taburet A. M., Lortholary O. other authors 2011; Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther 16:843–852 [CrossRef][PubMed]
    [Google Scholar]
  129. Le Douce V., Herbein G., Rohr O., Schwartz C. 2010; Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 7:32 [CrossRef][PubMed]
    [Google Scholar]
  130. Levy Y., Lacabaratz C., Weiss L., Viard J. P., Goujard C., Lelièvre J. D., Boué F., Molina J. M., Rouzioux C. other authors 2009; Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 119:997–1007[PubMed]
    [Google Scholar]
  131. Levy Y., Sereti I., Tambussi G., Routy J. P., Lelievre J. D., Delfraissy J. F., Molina J. M., Fischl M., Goujard C. other authors 2012; Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 55:291–300 [CrossRef][PubMed]
    [Google Scholar]
  132. Lewin S. R., Evans V. A., Elliott J. H., Spire B., Chomont N. 2011; Finding a cure for HIV: will it ever be achievable?. J Int AIDS Soc 14:4 [CrossRef][PubMed]
    [Google Scholar]
  133. Li Z., Guo J., Wu Y., Zhou Q. 2013; The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41:277–287 [CrossRef][PubMed]
    [Google Scholar]
  134. Lusic M., Marcello A., Cereseto A., Giacca M. 2003; Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 22:6550–6561 [CrossRef][PubMed]
    [Google Scholar]
  135. Mansky L. M., Temin H. M. 1995; Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087–5094[PubMed]
    [Google Scholar]
  136. Marcello A. 2006; Latency: the hidden HIV-1 challenge. Retrovirology 3:7[PubMed] [CrossRef]
    [Google Scholar]
  137. Margolis L., Shattock R. 2006; Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved?. Nat Rev Microbiol 4:312–317[PubMed] [CrossRef]
    [Google Scholar]
  138. Marini A., Harper J. M., Romerio F. 2008; An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 181:7713–7720[PubMed] [CrossRef]
    [Google Scholar]
  139. Marsden M. D., Zack J. A. 2009; Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63:7–10 [CrossRef][PubMed]
    [Google Scholar]
  140. Mbonye U., Karn J. 2011; Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 9:554–567 [CrossRef][PubMed]
    [Google Scholar]
  141. McDonnel S. J., Sparger E. E., Luciw P. A., Murphy B. G. 2012; Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. Virus Res 170:174–179 [CrossRef][PubMed]
    [Google Scholar]
  142. McMahon D., Jones J., Wiegand A., Gange S. J., Kearney M., Palmer S., McNulty S., Metcalf J. A., Acosta E. other authors 2010; Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50:912–919 [CrossRef][PubMed]
    [Google Scholar]
  143. McNamara L. A., Collins K. L. 2011; Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS 6:43–48 [CrossRef][PubMed]
    [Google Scholar]
  144. Middleton T., Lim H. B., Montgomery D., Rockway T., Tang H., Cheng X. H., Lu L. J., Mo H. M., Kohlbrenner W. E., Molla A. 2004; Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Res 64:35–45 [CrossRef][PubMed]
    [Google Scholar]
  145. Mowat A. M., Viney J. L. 1997; The anatomical basis of intestinal immunity. Immunol Rev 156:145–166 [CrossRef][PubMed]
    [Google Scholar]
  146. Murphy B., Vapniarsky N., Hillman C., Castillo D., McDonnel S., Moore P., Luciw P. A., Sparger E. E. 2012; FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection. Retrovirology 9:12 [CrossRef][PubMed]
    [Google Scholar]
  147. Neal T. F., Holland H. K., Baum C. M., Villinger F., Ansari A. A., Saral R., Wingard J. R., Fleming W. H. 1995; CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 86:1749–1756[PubMed]
    [Google Scholar]
  148. Nicholson J. K. A., Cross G. D., Callaway C. S., McDougal J. S. 1986; In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol 137:323–329[PubMed]
    [Google Scholar]
  149. North T. W., Higgins J., Deere J. D., Hayes T. L., Villalobos A., Adamson L., Shacklett B. L., Schinazi R. F., Luciw P. A. 2010; Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84:2913–2922 [CrossRef][PubMed]
    [Google Scholar]
  150. Novotney C., English R. V., Housman J., Davidson M. G., Nasisse M. P., Jeng C. R., Davis W. C., Tompkins M. B. 1990; Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS 4:1213–1218 [CrossRef][PubMed]
    [Google Scholar]
  151. O’Brien S. J., Moore J. P. 2000; The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 177:99–111 [CrossRef][PubMed]
    [Google Scholar]
  152. O’Doherty U., Swiggard W. J., Malim M. H. 2000; Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74:10074–10080 [CrossRef][PubMed]
    [Google Scholar]
  153. Ostrowski M. A., Chun T. W., Justement S. J., Motola I., Spinelli M. A., Adelsberger J., Ehler L. A., Mizell S. B., Hallahan C. W., Fauci A. S. 1999; Both memory and CD45RA+/CD62L+ naive CD4+ T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 73:6430–6435[PubMed]
    [Google Scholar]
  154. Oswald-Richter K., Grill S. M., Leelawong M., Unutmaz D. 2004; HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol 34:1705–1714 [CrossRef][PubMed]
    [Google Scholar]
  155. Pace M. J., Agosto L., Graf E. H., O’Doherty U. 2011; HIV reservoirs and latency models. Virology 411:344–354 [CrossRef][PubMed]
    [Google Scholar]
  156. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G. J., Brun S. C., Kempf D. J., Mellors J. W., Coffin J. M., King M. S. 2008; Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105:3879–3884 [CrossRef][PubMed]
    [Google Scholar]
  157. Palmer S., Josefsson L., Coffin J. M. 2011; HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 270:550–560 [CrossRef][PubMed]
    [Google Scholar]
  158. Parada C. A., Roeder R. G. 1996; Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384:375–378 [CrossRef][PubMed]
    [Google Scholar]
  159. Pattanayak V., Ramirez C. L., Joung J. K., Liu D. R. 2011; Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8:765–770 [CrossRef][PubMed]
    [Google Scholar]
  160. Pedersen N. C., Ho E. W., Brown M. L., Yamamoto J. K. 1987; Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790–793 [CrossRef][PubMed]
    [Google Scholar]
  161. Peer D., Karp J. M., Hong S., Farokhzad O. C., Margalit R., Langer R. 2007; Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760 [CrossRef][PubMed]
    [Google Scholar]
  162. Perez E. E., Wang J., Miller J. C., Jouvenot Y., Kim K. A., Liu O., Wang N., Lee G., Bartsevich V. V. other authors 2008; Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26:808–816 [CrossRef][PubMed]
    [Google Scholar]
  163. Pérez-Martínez D., Tanaka T., Rabbitts T. H. 2010; Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays 32:589–598 [CrossRef][PubMed]
    [Google Scholar]
  164. Pierson T., Hoffman T. L., Blankson J., Finzi D., Chadwick K., Margolick J. B., Buck C., Siliciano J. D., Doms R. W., Siliciano R. F. 2000; Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 74:7824–7833 [CrossRef][PubMed]
    [Google Scholar]
  165. Pierson T. C., Zhou Y., Kieffer T. L., Ruff C. T., Buck C., Siliciano R. F. 2002; Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 76:8518–8531 [CrossRef][PubMed]
    [Google Scholar]
  166. Prins J. M., Jurriaans S., van Praag R. M., Blaak H., van Rij R., Schellekens P. T., ten Berge I. J., Yong S. L., Fox C. H. other authors 1999; Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405–2410 [CrossRef][PubMed]
    [Google Scholar]
  167. Ramratnam B., Mittler J. E., Zhang L., Boden D., Hurley A., Fang F., Macken C. A., Perelson A. S., Markowitz M., Ho D. D. 2000; The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6:82–85 [CrossRef][PubMed]
    [Google Scholar]
  168. Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J. S., Quivy V., Vanhulle C., Lamine A., Vaira D. other authors 2009; Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4:e6093 [CrossRef][PubMed]
    [Google Scholar]
  169. Richman D. D., Margolis D. M., Delaney M., Greene W. C., Hazuda D., Pomerantz R. J. 2009; The challenge of finding a cure for HIV infection. Science 323:1304–1307 [CrossRef][PubMed]
    [Google Scholar]
  170. Roesch F., Meziane O., Kula A., Nisole S., Porrot F., Anderson I., Mammano F., Fassati A., Marcello A. other authors 2012; Hyperthermia stimulates HIV-1 replication. PLoS Pathog 8:e1002792 [CrossRef][PubMed]
    [Google Scholar]
  171. Rossi M. I., Medina K. L., Garrett K., Kolar G., Comp P. C., Shultz L. D., Capra J. D., Wilson P., Schipul A., Kincade P. W. 2001; Relatively normal human lymphopoiesis but rapid turnover of newly formed B cells in transplanted nonobese diabetic/SCID mice. J Immunol 167:3033–3042[PubMed] [CrossRef]
    [Google Scholar]
  172. Ruff C. T., Ray S. C., Kwon P., Zinn R., Pendleton A., Hutton N., Ashworth R., Gange S., Quinn T. C. other authors 2002; Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 76:9481–9492 [CrossRef][PubMed]
    [Google Scholar]
  173. Rullas J., Bermejo M., García-Pérez J., Beltán M., González N., Hezareh M., Brown S. J., Alcamí J. 2004; Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther 9:545–554[PubMed]
    [Google Scholar]
  174. Sahu G. K., Lee K., Ji J. X., Braciale V., Baron S., Cloyd M. W. 2006; A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 355:127–137 [CrossRef][PubMed]
    [Google Scholar]
  175. Sahu G. K., Paar D., Frost S. D. W., Smith M. M., Weaver S., Cloyd M. W. 2009; Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 81:9–15 [CrossRef][PubMed]
    [Google Scholar]
  176. Saleh S., Solomon A., Wightman F., Xhilaga M., Cameron P. U., Lewin S. R. 2007; CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110:4161–4164 [CrossRef][PubMed]
    [Google Scholar]
  177. Saleh S., Wightman F., Ramanayake S., Alexander M., Kumar N., Khoury G., Pereira C., Purcell D., Cameron P. U., Lewin S. R. 2011; Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology 8:80 [CrossRef][PubMed]
    [Google Scholar]
  178. Schnittman S. M., Psallidopoulos M. C., Lane H. C., Thompson L., Baseler M., Massari F., Fox C. H., Salzman N. P., Fauci A. S. 1989; The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245:305–308 [CrossRef][PubMed]
    [Google Scholar]
  179. Schröder A. R., Shinn P., Chen H., Berry C., Ecker J. R., Bushman F. 2002; HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521–529 [CrossRef][PubMed]
    [Google Scholar]
  180. Scripture-Adams D. D., Brooks D. G., Korin Y. D., Zack J. A. 2002; Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76:13077–13082 [CrossRef][PubMed]
    [Google Scholar]
  181. Shan L., Deng K., Shroff N. S., Durand C. M., Rabi S. A., Yang H. C., Zhang H., Margolick J. B., Blankson J. N., Siliciano R. F. 2012; Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491–501 [CrossRef][PubMed]
    [Google Scholar]
  182. Shen A. D., Zink M. C., Mankowski J. L., Chadwick K., Margolick J. B., Carruth L. M., Li M., Clements J. E., Siliciano R. F. 2003; Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 77:4938–4949 [CrossRef][PubMed]
    [Google Scholar]
  183. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E. L., Haining H., Akashi H., Takeuchi Y., Hosie M. J., Willett B. J. 2004; Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303:1192–1195 [CrossRef][PubMed]
    [Google Scholar]
  184. Siliciano, R. F. & Greene, W. C. (2011 HIV Latency. Cold Spring Harbor Perspectives in Medicine 1
  185. Siliciano J. D., Siliciano R. F. 2010; Biomarkers of HIV replication. Curr Opin HIV AIDS 5:491–497 [CrossRef][PubMed]
    [Google Scholar]
  186. Siliciano J. D., Kajdas J., Finzi D., Quinn T. C., Chadwick K., Margolick J. B., Kovacs C., Gange S. J., Siliciano R. F. 2003; Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728 [CrossRef][PubMed]
    [Google Scholar]
  187. Sloan R. D., Wainberg M. A. 2011; The role of unintegrated DNA in HIV infection. Retrovirology 8:52 [CrossRef][PubMed]
    [Google Scholar]
  188. Stanley S. K., Kessler S. W., Justement J. S., Schnittman S. M., Greenhouse J. J., Brown C. C., Musongela L., Musey K., Kapita B., Fauci A. S. 1992; CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 149:689–697[PubMed]
    [Google Scholar]
  189. Stevenson M., Stanwick T. L., Dempsey M. P., Lamonica C. A. 1990; HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9:1551–1560[PubMed]
    [Google Scholar]
  190. Svarovskaia E. S., Barr R., Zhang X. C., Pais G. C. G., Marchand C., Pommier Y., Burke T. R. Jr, Pathak V. K. 2004; Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 78:3210–3222 [CrossRef][PubMed]
    [Google Scholar]
  191. Swan C. H., Bühler B., Tschan M. P., Barbas C. F., Torbett B. E. 2006; T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13:1480–1492 [CrossRef][PubMed]
    [Google Scholar]
  192. Tobin N. H., Learn G. H., Holte S. E., Wang Y., Melvin A. J., McKernan J. L., Pawluk D. M., Mohan K. M., Lewis P. F. other authors 2005; Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79:9625–9634 [CrossRef][PubMed]
    [Google Scholar]
  193. Tompkins M. B., Tompkins W. A. 2008; Lentivirus-induced immune dysregulation. Vet Immunol Immunopathol 123:45–55 [CrossRef][PubMed]
    [Google Scholar]
  194. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J. C., Lanzavecchia A., Manz M. G. 2004; Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104–107 [CrossRef][PubMed]
    [Google Scholar]
  195. Trautmann L., Janbazian L., Chomont N., Said E. A., Gimmig S., Bessette B., Boulassel M.-R., Delwart E., Sepulveda H. other authors 2006; Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12:1198–1202 [CrossRef][PubMed]
    [Google Scholar]
  196. Tyagi M., Pearson R. J., Karn J. 2010; Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 84:6425–6437 [CrossRef][PubMed]
    [Google Scholar]
  197. Tzachanis D., Lafuente E. M., Li L., Boussiotis V. A. 2004; Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma 45:1959–1967 [CrossRef][PubMed]
    [Google Scholar]
  198. Urnov F. D., Miller J. C., Lee Y.-L., Beausejour C. M., Rock J. M., Augustus S., Jamieson A. C., Porteus M. H., Gregory P. D., Holmes M. C. 2005; Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435:646–651 [CrossRef][PubMed]
    [Google Scholar]
  199. Van Duyne R., Pedati C., Guendel I., Carpio L., Kehn-Hall K., Saifuddin M., Kashanchi F. 2009; The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 6:76 [CrossRef][PubMed]
    [Google Scholar]
  200. van Grevenynghe J., Procopio F. A., He Z., Chomont N., Riou C., Zhang Y., Gimmig S., Boucher G., Wilkinson P. other authors 2008; Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nat Med 14:266–274 [CrossRef][PubMed]
    [Google Scholar]
  201. van Leeuwen E. M. M., Sprent J., Surh C. D. 2009; Generation and maintenance of memory CD4+ T cells. Curr Opin Immunol 21:167–172 [CrossRef][PubMed]
    [Google Scholar]
  202. Van Lint C., Emiliani S., Ott M., Verdin E. 1996; Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112–1120[PubMed]
    [Google Scholar]
  203. Vatakis D. N., Bristol G., Wilkinson T. A., Chow S. A., Zack J. A. 2007; Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol 81:3574–3582 [CrossRef][PubMed]
    [Google Scholar]
  204. Vatakis D. N., Kim S., Kim N., Chow S. A., Zack J. A. 2009; Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol 83:6222–6233 [CrossRef][PubMed]
    [Google Scholar]
  205. Vatakis D. N., Nixon C. C., Zack J. A. 2010; Quiescent T cells and HIV: an unresolved relationship. Immunol Res 48:110–121 [CrossRef][PubMed]
    [Google Scholar]
  206. Verdin E., Paras P. Jr, Van Lint C. 1993; Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249–3259[PubMed]
    [Google Scholar]
  207. Volberding P. A., Deeks S. G. 2010; Antiretroviral therapy and management of HIV infection. Lancet 376:49–62 [CrossRef][PubMed]
    [Google Scholar]
  208. Wang F. X., Xu Y., Sullivan J., Souder E., Argyris E. G., Acheampong E. A., Fisher J., Sierra M., Thomson M. M. other authors 2005; IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115:128–137[PubMed] [CrossRef]
    [Google Scholar]
  209. Weissman D., Rabin R. L., Arthos J., Rubbert A., Dybul M., Swofford R., Venkatesan S., Farber J. M., Fauci A. S. 1997; Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389:981–985 [CrossRef][PubMed]
    [Google Scholar]
  210. Wightman F., Solomon A., Khoury G., Green J. A., Gray L., Gorry P. R., Ho Y. S., Saksena N. K., Hoy J. other authors 2010; Both CD31+ and CD31⁻ naive CD4+ T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 202:1738–1748 [CrossRef][PubMed]
    [Google Scholar]
  211. Wightman F., Ellenberg P., Churchill M., Lewin S. R. 2012; HDAC inhibitors in HIV. Immunol Cell Biol 90:47–54 [CrossRef][PubMed]
    [Google Scholar]
  212. Wilen C. B., Wang J., Tilton J. C., Miller J. C., Kim K. A., Rebar E. J., Sherrill-Mix S. A., Patro S. C., Secreto A. J. other authors 2011; Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 7:e1002020 [CrossRef][PubMed]
    [Google Scholar]
  213. Willett B. J., Picard L., Hosie M. J., Turner J. D., Adema K., Clapham P. R. 1997; Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71:6407–6415[PubMed]
    [Google Scholar]
  214. Williams S. A., Greene W. C. 2007; Regulation of HIV-1 latency by T-cell activation. Cytokine 39:63–74 [CrossRef][PubMed]
    [Google Scholar]
  215. Williams S. A., Kwon H., Chen L. F., Greene W. C. 2007; Sustained induction of NF-κB is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 81:6043–6056 [CrossRef][PubMed]
    [Google Scholar]
  216. Wolschendorf F., Duverger A., Jones J., Wagner F. H., Huff J., Benjamin W. H., Saag M. S., Niederweis M., Kutsch O. 2010; Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 84:8712–8720 [CrossRef][PubMed]
    [Google Scholar]
  217. Wu Y. T., Yoder A. 2009; Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 5:e1000520 [CrossRef][PubMed]
    [Google Scholar]
  218. Wu L. J., Paxton W. A., Kassam N., Ruffing N., Rottman J. B., Sullivan N., Choe H., Sodroski J., Newman W. other authors 1997; CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185:1681–1692 [CrossRef][PubMed]
    [Google Scholar]
  219. Xing S., Bullen C. K., Shroff N. S., Shan L., Yang H. C., Manucci J. L., Bhat S., Zhang H., Margolick J. B. other authors 2011; Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85:6060–6064 [CrossRef][PubMed]
    [Google Scholar]
  220. Xing S. F., Bhat S., Shroff N. S., Zhang H., Lopez J. A., Margolick J. B., Liu J. O., Siliciano R. F. 2012; Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 67:398–403 [CrossRef][PubMed]
    [Google Scholar]
  221. Yamamoto J. K., Sparger E., Ho E. W., Andersen P. R., O’Connor T. P., Mandell C. P., Lowenstine L., Munn R., Pedersen N. C. 1988; Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 49:1246–1258[PubMed]
    [Google Scholar]
  222. Yamamoto J. K., Hansen H., Ho E. W., Morishita T. Y., Okuda T., Sawa T. R., Nakamura R. M., Pedersen N. C. 1989; Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc 194:213–220[PubMed]
    [Google Scholar]
  223. Yang H. C. 2011; Primary cell models of HIV latency. Curr Opin HIV AIDS 6:62–67 [CrossRef][PubMed]
    [Google Scholar]
  224. Yang H. C., Xing S. F., Shan L., O’Connell K., Dinoso J., Shen A. D., Zhou Y., Shrum C. K., Han Y. F. other authors 2009; Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 119:3473–3486[PubMed]
    [Google Scholar]
  225. Yeung F., Hoberg J. E., Ramsey C. S., Keller M. D., Jones D. R., Frye R. A., Mayo M. W. 2004; Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380 [CrossRef][PubMed]
    [Google Scholar]
  226. Ylisastigui L., Archin N. M., Lehrman G., Bosch R. J., Margolis D. M. 2004; Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101–1108 [CrossRef][PubMed]
    [Google Scholar]
  227. Yoder A., Yu D. Y., Dong L., Iyer S. R., Xu X. H., Kelly J., Liu J., Wang W. F., Vorster P. J. other authors 2008; HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134:782–792 [CrossRef][PubMed]
    [Google Scholar]
  228. Yuan J., Wang J., Crain K., Fearns C., Kim K. A., Hua K. L., Gregory P. D., Holmes M. C., Torbett B. E. 2012; Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4+ T cell resistance and enrichment. Mol Ther 20:849–859 [CrossRef][PubMed]
    [Google Scholar]
  229. Yukl S. A., Shergill A. K., McQuaid K., Gianella S., Lampiris H., Hare C. B., Pandori M., Sinclair E., Günthard H. F. other authors 2010; Effect of Raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24:2451–2460 [CrossRef][PubMed]
    [Google Scholar]
  230. Yusuf I., Fruman D. A. 2003; Regulation of quiescence in lymphocytes. Trends Immunol 24:380–386 [CrossRef][PubMed]
    [Google Scholar]
  231. Zagury D., Bernard J., Leonard R., Cheynier R., Feldman M., Sarin P. S., Gallo R. C. 1986; Long-term cultures of HTLV-III–infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 231:850–853 [CrossRef][PubMed]
    [Google Scholar]
  232. Zhou Y., Zhang H., Siliciano J. D., Siliciano R. F. 2005; Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79:2199–2210 [CrossRef][PubMed]
    [Google Scholar]
  233. Zhu T., Mo H., Wang N., Nam D. S., Cao Y., Koup R. A., Ho D. D. 1993; Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179–1181 [CrossRef][PubMed]
    [Google Scholar]
  234. Zhu J., Gaiha G. D., John S. P., Pertel T., Chin C. R., Gao G., Qu H., Walker B. D., Elledge S. J., Brass A. L. 2012; Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2:807–816 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.049296-0
Loading
/content/journal/jgv/10.1099/vir.0.049296-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error